A Dynamic DNA Nano‐Antioxidant Targeting Galectin‐3 Attenuates Liver Fibrosis via Reducing Macrophage Oxidative Stress
Advanced Science · 2026-01 · 13 (4)
DOI: 10.1002/advs.202509977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.10.2025. Verfasst von Mengjia Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, the General Hospital of Tibet Military Command, Lhasa, China. Hauptthemen laut MEDLINE: Oxidative Stress, Antioxidants, Macrophages, Liver Cirrhosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Projects of Xizang Autonomous Region, China.
Abstract (Originalsprache)
Liver cirrhosis represents a major global health challenge with significant socioeconomic implications. Oxidative stress‐mediated injury plays a pivotal role in driving fibrotic progression, with hepatic macrophages serving as a dominant source of reactive oxygen species (ROS). Consequently, targeted suppression of macrophage‐derived ROS presents a promising therapeutic strategy. Single‐cell RNA sequencing analysis identified Galectin‐3 as positively correlated with macrophage oxidative stress and ROS production. Here, a dynamic DNA nano‐antioxidant (DDN) is developed for hepatic macrophage‐specific small interfering RNA (siRNA) delivery targeting Galectin‐3. DDN administration achieved a 3.92‐fold reduction in Galectin‐3 expression, with transcriptomic profiling revealing restoration of Nuclear Factor Erythroid 2‐Related Factor 2 (NRF2) signaling and consequent attenuation of oxidative stress in macrophages. Pharmacokinetic assessment via IVIS imaging demonstrated superior hepatic accumulation of DDN, exhibiting 1.57‐ and 2.11‐fold greater fluorescence intensity at 240 min post‐injection compared to siRNA and tetrahedral framework nucleic acid (tFNA), respectively. In a carbon tetrachloride (CCl 4 )‐induced mouse model, intraperitoneal DDN administration significantly reduced macrophage oxidative burden, ROS generation, and M1 polarization, ultimately mitigating collagen deposition and fibrotic progression. These findings establish DDN as a potent and targeted therapeutic platform for liver fibrosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency, the General Hospital of Tibet Military Command, Lhasa, China.
- Department of Gastroenterology, Laboratory of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
- State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
- Physical Examination Center, General Hospital of Western Theater Command, Chengdu, China.
ORCID-Profile: Bowen Wang
Förderung
- National Natural Science Foundation of China
- Science and Technology Projects of Xizang Autonomous Region, China
Zitieren
APA
Peng, M., Xu, J., Hong, Y., Fang, F., Li, Y., Ci, D., & Wang, B. (2026). A Dynamic DNA Nano‐Antioxidant Targeting Galectin‐3 Attenuates Liver Fibrosis via Reducing Macrophage Oxidative Stress. Advanced Science, 13(4). https://doi.org/10.1002/advs.202509977
Vancouver
Peng M, Xu J, Hong Y, Fang F, Li Y, Ci D, et al. A Dynamic DNA Nano‐Antioxidant Targeting Galectin‐3 Attenuates Liver Fibrosis via Reducing Macrophage Oxidative Stress. Advanced Science. 2026;13(4). doi:10.1002/advs.202509977
BibTeX
@article{Peng2026,
author = {Peng, Mengjia and Xu, Jianguo and Hong, Youjian and Fang, Fei and Li, Yan and Ci, Duo and Wang, Bowen},
title = {A Dynamic DNA Nano‐Antioxidant Targeting Galectin‐3 Attenuates Liver Fibrosis via Reducing Macrophage Oxidative Stress},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {4},
doi = {10.1002/advs.202509977}
}
EUVIMED